US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:04:51 Source:styleViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Mohammad Mokhber: Who is Iran’s acting president?
Next:Strictly star Giovanni Pernice's former partner Rose Ayling
You may also like
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
- Government departments defend staffing increase in late 2023
- Exploited migrants: New language rules may force workers still in debt to leave NZ
- Senior US diplomat suggests AUKUS will deter any China moves against Taiwan
- LeBron James UNFOLLOWS Diddy on Instagram after video of assault on ex
- Golriz Ghahraman's law career at risk if convicted, professor says
- Wellington City Council seeks feedback on its 10
- Viable but risky: Former Whakapapa ski field bidder
- Defending champion South Carolina to open season in Las Vegas against Michigan